Back to Journals » International Journal of General Medicine » Volume 12

Mini-review: medication safety of red yeast rice products

Authors Farkouh A , Baumgärtel C

Received 22 January 2019

Accepted for publication 21 March 2019

Published 30 April 2019 Volume 2019:12 Pages 167—171

DOI https://doi.org/10.2147/IJGM.S202446

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Scott Fraser



André Farkouh,1 Christoph Baumgärtel2

1Division of Clinical Pharmacy and Diagnostics, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, A-1090, Austria; 2AGES Austrian Medicines and Medical Devices Agency and Austrian Federal Office for Safety in Health Care, A-1200 Vienna, Austria

Abstract: High lipid levels in the blood together with high blood pressure and diabetes are among the highest risks for coronary heart disease. In particular, elevated cholesterol levels promote the progression of atherosclerosis. Red yeast rice, also called red fermented rice or red mold rice, is used as a dietary supplement to lower cholesterol levels. It contains varying amounts of natural monacolin K, which is a structural homolog to lovastatin, and shows hypocholesterolemic properties comparable to synthetic statins. Despite being portrayed as a natural alternative, the potential of red yeast rice for side effects and interactions is comparable to statin drugs. Consumers need to be made aware of the varying monacolin K content in red yeast rice products and the insufficient long-term safety data regarding the potential risks of red yeast rice.

Keywords: red yeast rice, monacolin K, p-glycoprotein, pharmacokinetics

Introduction

Hypolipidemic medicinal products belonging to the statin class of drugs inhibit the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the key enzyme in cholesterol biosynthesis that converts HMG-CoA into mevalonate. Due to the reduced cholesterol synthesis, LDL-cholesterol is increasingly broken down and HDL-cholesterol is increasingly formed. In addition, other pleiotropic effects of statins, such as anti-inflammatory, antioxidant or direct vascular effects, are described in the literature.1

The substances available on the market differ considerably in efficacy as well as adverse effects and interactions. Muscle symptoms associated with statins range from mild muscle pain to myopathy, and, in extremely rare cases, even to dangerous rhabdomyolysis that can lead to renal impairment.2 Furthermore, statins can cause new-onset diabetes mellitus that contributes to the risk for hemorrhagic stroke.2 Elevated levels of liver enzymes have also been reported, yet, events of serious liver injuries are rare.2 In this context it should be noted that in view of the millions of prescriptions of statins they are generally considered to be a very safe class of drugs.

Although dietary interventions and an active lifestyle are generally recommended to decrease cardiovascular risk, these preventive measures may not directly affect the LDL levels.3

For patients with hypercholesterolemia that are not qualified for treatment with statin drugs based on their cardiovascular risk, nutraceuticals like red yeast rice products, which are available without prescription in Europe, are seen by some as a possible further preventive measure that can induce a clinical meaningful decrease of up to 25% in LDL levels.3

In addition, red yeast rice is currently being discussed as an alternative treatment option for statin intolerant patients, as statin intolerance refers to statin associated muscle symptoms that lead to discontinuation rather than complete intolerance.4 Further, combined nutraceuticals may be a new approach to treat statin intolerant patients, making use of potentially additive mechanism of action.5

The regulatory status of nutraceuticals and particularly red yeast rice is still under debate.6 In contrast to food supplements that exhibit nutritional value, nutraceuticals show specific pharmacological activities.6 Therefore, efficacy and safety need to be assessed and dose limits need to be regulated.6 The risks associated with the use of red yeast rice, the alleged natural alternative to statins, are discussed in this review.

Data sources, searches, and extraction

Relevant articles published between April 2001 and January 2019 were searched using PubMed (incl. PubMed Central and Medline) and an Austrian data source (Austria Codex). Combinations of key terms, which included “red yeast rice”, “pharmacokinetics”, “monacolin K”, “p-glycoprotein”, “side effects”, “pharmacodynamics” and “lovastatin” were used. Additionally, reference lists of the included articles and key systemic reviews were checked manually.

Pharmacological effects and interactions of red yeast rice

Red yeast rice is offered as a dietary supplement, alone or in combination with a balanced diet, to patients with dyslipidemia.7,8 It is not a separate rice variety, but produced by the fermentation of ordinary rice (Oryza sativa) with a certain mold fungus of the Monascus genus. During the fermentation, red dyes and various other potentially pharmacologically and toxicologically active ingredients are produced,9 including monacolin K which is identical to the statin drug lovastatin.10

While often portraited otherwise in the media, taking red yeast rice products actually has similar effects to taking lovastatin, even though the potency is significantly lower, and the potential for side effects and interactions similar to those of statin drugs is to be assumed.1113 The prodrug lovastatin, after gastrointestinal absorption and hydrolysis into the active hydroxy acid form, is metabolized mainly in the liver by CYP-3A4. Hence, numerous interactions can occur.1,14

Strong CYP-3A4 inhibitors, in particular, can increase the risk of myopathy by increasing the drug plasma concentration and consequently the inhibition of the HMG-CoA reductase during lovastatin or red yeast rice therapy.15 These inhibitors include, for example, cyclosporin, itraconazole, clarithromycin, verapamil, aprepitant, amiodarone as well as HIV protease inhibitors such as ritonavir and other cholesterol lowering agents such as fibrates.15,16

Grapefruit juice, if consumed in large amounts, may also significantly increase the inhibitory activity of lovastatin on HMG-CoA reductase.15 Furthermore, there is clear evidence that lovastatin inhibits the membrane transport protein P-glycoprotein, which plays an important role in the detoxification of drugs.1,17,18

This efflux transporter, which is predominantly found in excretory tissues, actively transports not only endogenous substances, such as steroids and cytokines, but also potentially toxic xenobiotics out of cells. Thus, the inhibitory effect of monacolin K (lovastatin) on this transporter can also significantly influence the bioavailability and the distribution of drugs.17,18

Variability of monacolin content of red yeast rice products

It is evident from the literature that the ratio of monacolin K and its hydroxyl acid form monacolin KA varies widely in various red yeast rice products.19 This results in variable bioavailability, because monacolin KA, the active form, is much more readily absorbed.19

Concentrations of HMG-CoA reductase inhibitors in red yeast rice products can be increased by optimization of the fermentation conditions and selection of the rice variety.20,21 In cultures with Thai rice (Oryza sativa L.) cv. RD6, up to 34 mg monacolin K as well as 22 mg compactin (desmethyl-monacolin K, mevastatin) per gram of powder can be found among other monacolines.22

It is also worth mentioning that the biological activity of the other monacolins occurring in red rice, such as the previously mentioned compactin, have not been considered so far. Compactin is likely to be only half as effective with respect to HMG-CoA reductase inhibition as monacolin K.20,21 Therefore, the bioavailability of the individual monacolins is difficult to determine in the presence of monacolin K. It may be useful to specify a total monacolin content in the form of “monacolin equivalents”.

The literature points out a lack of standardization of monacolin content and also the detection of the mycotoxin citrinin.23 Citrinin is described as nephrotoxic and teratogenic and resulted in the development of renal tumors in rats.24

Finally, it should also be noted that taking red yeast rice products and statins at the same time can easily lead to overdosing and side effects. On a side note, lovastatin should also be used with caution in patients who consume significant amounts of alcohol and/or have a history of liver disease.15

Safety profile of red yeast rice

The safety of red yeast rice alone or in combined nutraceuticals has been investigated in clinical trials, where low (3 mg/day) as well as high dose (10 mg/day) regimes of monacolin K were well tolerated by patients with dyslipidemia, with few or no adverse events.2528 In combination with a low-dose statin therapy, a nutraceutical combination containing red yeast rice has been shown to be tolerated equally to a low-dose statin therapy alone in high-risk patients that were high-dose statin intolerant.29 However, since the majority of the clinical trials had a short treatment duration of about four to twelve weeks, assessment of long-term side effects is limited.

Adverse effects associated with red yeast rice that are repeatedly reported, include symptomatic myopathy,3032 gastrointestinal symptoms,31,33 and elevated levels of hepatic enzymes indicative for liver injury.3133 Recently, exacerbation of myasthenia gravis and development of erectile dysfunction have also been attributed to red yeast rice intake in two individual cases.34,35

Overall, the majority of adverse effects reported for red yeast rice are also commonly associated with statin drugs.31,33

The safety profile of red yeast rice is mainly based on case reports and assessment is complicated by self-medication and varying product composition. Continuous monitoring and further long-term trials are indispensable.

Misleading reporting

Misrepresentations of red yeast rice products in the media may give patients the impression that an adequate intake of red yeast rice products can provide sufficient treatment for dyslipidemia.36,37 However, this is grossly negligent, especially in the secondary prophylaxis of cardiovascular events which requires sufficient efficacy levels of a potent statin for therapeutic success.3638

It should also be noted that consumers often assume dietary supplements to be less dangerous. In the case of red yeast rice this can be very deceptive and even harmful. Statins, and thus also red yeast rice products, are generally contraindicated during pregnancy and lactation due to their teratogenicity observed in animal experiments.15

Another major factor of uncertainty is the self-medication outside of medical monitoring and the fact that there is no systematic recording of adverse effects, as required by law for authorized drugs.3639

Conclusion

The claim that red yeast rice “naturally” lowers or maintains cholesterol levels without comparable side-effects to synthetic statins is untenable. Furthermore, monacolin K cannot be considered a common nutrient as it is rare in common foods. In corresponding studies on fungi, such as mushrooms or oyster mushrooms, only trace amounts could be detected.40 It is recommended that red yeast rice products are only made available with appropriate warnings as they have the same clinically relevant risk potential as statins.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Freissmuth M, Offermanns S, Böhm S. Pharmakologie und Toxikologie: Von den molekularen Grundlagen zur Pharmakotherapie. 2nd ed. Berlin (Heidelberg): Springer Verlag; 2016:499–501. German.

2. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561. doi:10.1016/S0140-6736(16)31357-5

3. Poli A, Barbagallo CM, Cicero AFG, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res. 2018;134:51–60. doi:10.1016/j.phrs.2018.05.015

4. Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96–118. doi:10.1016/j.jacc.2018.04.040

5. Marchitto N, Sindona F, Fabrizio A, et al. Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome. Minerva Cardioangiol. 2018;66(1):124–125. doi:10.23736/S0026-4725.17.04523-6

6. Santini A, Cammarata SM, Capone G, et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–672. doi:10.1111/bcp.13496

7. Klimek M, Wang S, Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. ‎Pharm Ther. 2009;34(6):313–327.

8. Lin JS. An alternative treatment of hyperlipidemia with red yeast rice: a case report. J Med Case Rep. 2010;4:4. doi:10.1186/1752-1947-4-4

9. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830–839.

10. Lin C-C, Li T-C, Lai M-M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153(5):679–686. doi:10.1530/eje.1.02012

11. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96(12):1265–1267. doi:10.1097/01.SMJ.0000100117.79718.DC

12. Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4):572–574. doi:10.1111/j.1365-2125.2008.03224.x

13. Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol. 2008;2(1):60–62. doi:10.1016/j.jacl.2007.12.005

14. Tonner PH, Hein L. Pharmakotherapie in der Anästhesie und Intensivmedizin. Berlin (Heidelberg): Springer Verlag; 2011:261–262. German.

15. Lovastatin Hexal 20 mg-Tabletten [prescribing information]. Austria codex. Österreichische Apotheker-Verlagsgesellschaft mbH. January 2019. German.

16. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74(8):1200–1201. doi:10.1097/01.TP.0000031950.34040.79

17. Hong S-P, Yang J-S, Han J-Y, et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol. 2011;63(1):129–135.

18. Choi D-H, Chung J-H, Choi J-S. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol. 2010;66(3):285–290. doi:10.1007/s00228-009-0757-x

19. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722–1727. doi:10.1001/archinternmed.2010.382

20. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7(2):133–139. doi:10.1089/107555301750164181

21. Li Y-G, Zhang F, Wang Z-T, Hu Z-B. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35(5):1101–1112. doi:10.1016/j.jpba.2004.04.004

22. Chairote E-O, Lumyong S, Chairote G. Study on cholesterol lowering compounds in red yeast rice prepared from thai glutinous rice. In: International conference on the Role of Universities in Hands-on Education, Rajamangala University of Technology Lanna; August 23–29, 2009:196–208; Chiang-Mai, Thailand. doi:10.1177/1753193408098902

23. Ji X, Xu J, Wang X, et al. Citrinin determination in red fermented rice products by optimized extraction method coupled to liquid chromatography tandem mass spectrometry (LC-MS/MS). J Food Sci. 2015;80(6):T1438–T1444. doi:10.1111/1750-3841.12900

24. BVL, BfArM. Einstufung von Rotschimmelreisprodukten. Stellungnahme der gemeinsamen Expertenkommission BVL/BfArM. February 2016. Available from: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgrenzung/Expertenkommission/stellungnahmen/2016-02.pdf?__blob=publicationFile&v=5. Accessed March 19, 2019. German.

25. Mazza A, Schiavon L, Rigatelli G, Torin G, Montanaro F, Lenti S. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct. 2018;9(7):3845–3852. doi:10.1039/c8fo00415c

26. Spigoni V, Aldigeri R, Antonini M, et al. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. Int J Mol Sci. 2017;18(7):1498. doi:10.3390/ijms18071498

27. Cicero AF, Colletti A, Fogacci F, Bove M, Rosticci M, Borghi C. Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial. High Blood Press Cardiovasc Prev. 2017;24(1):13–18. doi:10.1007/s40292-016-0163-2

28. Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9(6):e98611. doi:10.1371/journal.pone.0098611

29. Marazzi G, Campolongo G, Pelliccia F, et al. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am J Cardiol. 2017;120(6):893–897. doi:10.1016/j.amjcard.2017.06.015

30. Philibert C, Bres V, Jean-Pastor MJ, et al. [Red yeast-rice-induced muscular injuries: analysis of French pharmacovigilance database and literature review]. Therapie. 2016. pii: S0040-5957(16)30054-3. French.

31. Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83(4):894–908. doi:10.1111/bcp.13171

32. Raschi E, Girardi A, Poluzzi E, et al. Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems. Drug Saf. 2018;41(8):745–752. doi:10.1007/s40264-018-0661-3

33. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J Clin Pharm Ther. 2016;41(2):170–179. doi:10.1111/jcpt.12374

34. Dobremez V, Serra A, Grosset-Janin D, Dopter A, Pineau-Blondel E, Ruel J-H. Myasthenia gravis exacerbation after red yeast rice use. Rev Neurol (Paris). 2018;174(7–8):577–578. doi:10.1016/j.neurol.2017.08.006

35. Liu Z, Chen P. A case of erectile dysfunction induced by red yeast rice in lipid-lowering therapy. Phytother Res. 2018;32(5):953–954. doi:10.1002/ptr.6025

36. BfArM. Pressemitteilung 3/16 – bfArM warnt erneut vor Red Rice-Nahrungsergänzungsmitteln: produkte ab einer Tagesdosis von 5 mg Monakolin K sind als Arzneimittel einzustufen. 2016. Available from: https://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2016/pm3-2016.html. Accessed March 19, 2019. German.

37. FDA. FDA warns consumers to avoid red yeast rice products promoted on internet as treatments for high cholesterol products found to contain unauthorized drug. August 09, 2007. Available from: https://wayback.archive-it.org/7993/20161022045125/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm108962.htm. Accessed October 05, 2018.

38. Swissmedic. Vermarktung von Präparaten mit Monascus purpureus (Rotschimmelreis, rote Reishefe) ist in der Schweiz nicht zulässig. February 28, 2014. Avaliable from: https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/abrenzungsfragen/vermarktung_von_praeparatenmitmonascuspurpureusrotschimmelreisro.pdf.download.pdf/vermarktung_von_praeparatenmitmonascuspurpureusrotschimmelreisro.pdf. Accessed March 19, 2019. German.

39. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145(6):474–475.

40. Stephan K. Red rice – Wirkungen und Nebenwirkungen von Produkten aus Rotschimmelreis. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) Bulletin zur Arzneimittelsicherheit. 2016;(2):6–11. Avaliable from: https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Bulletin/2016/2-2016.pdf?__blob=publicationFile&v=5. Accessed March 19, 2019. German.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.